Cogent Biosciences signs Hovione supply deal for bezuclastinib tablets

Cogent Biosciences signed a commercial supply agreement with Hovione on Sept. 1, 2026, covering bezuclastinib spray-dried dispersion and tablets.

• Purchases are set through rolling quarterly forecasts, with a near-term binding portion; Cogent must source minimum requirement shares from Hovione.
• The initial term is five years, followed by automatic two-year renewals.
• Termination rights include breach, force majeure, insolvency, and regulatory or legal changes.